SRC family kinase activity is up-regulated in hormone-refractory prostate cancer

Oleg Tatarov, Thomas J Mitchell, Morag Seywright, Hing Y Leung, Valerie G Brunton, Joanne Edwards

Research output: Contribution to journalArticlepeer-review

Abstract

Although Src family kinase (SFK) inhibitors are now in clinical trials for the treatment of androgen-independent prostate cancer (AIPC), there are no studies relating SFK activation to patient survival. This study was designed to determine if SFK activation was up-regulated with the development of AIPC and if patients could be selected who were more likely to respond to therapy.
Original languageEnglish
Pages (from-to)3540-9
Number of pages10
JournalClinical Cancer Research
Volume15
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint Dive into the research topics of 'SRC family kinase activity is up-regulated in hormone-refractory prostate cancer'. Together they form a unique fingerprint.

Cite this